标题：希罗达联合同步放化疗治疗晚期直肠癌疗效分析

      作者：武星 1，杜敏 1，蒋瑜婷 1，胡晓莉 1，蔡东焱 2
    (无锡市第四人民医院药剂科 1、肿瘤科 2，江苏 无锡 214062)

      卷次： 2016年27卷12期

      【摘要】 目的 观察希罗达联合同步放化疗治疗晚期直肠癌的临床效果。方法 选择2010年4月至2012年
12月在我院肿瘤科接受治疗的晚期直肠癌患者116例，以随机数表法随机分为观察组和对照组各58例。对照组单
用希罗达进行化疗，观察组采用希罗达联合放疗同步治疗。比较两组患者的治疗效果、治疗后不良反应、并发症，
随访3年记录生存情况。结果 观察组患者治疗后的CR比例及有效率分别为45.55% (27/58)、81.03% (47/58)，均明
显高于对照组的27.59% (16/58)、56.09% (33/58)，差异均有统计学意义(P<0.05)；观察组患者出现血小板减少、血红
蛋白降低以及淋巴细胞减少的比例分别为 34.48% (20/58)、20.69% (12/58)、15.52% (9/58)，均明显低于对照组的
53.45% (31/58)、39.66% (23/58)、31.03% (18/58)，但放射性直肠炎发生率为 46.55% (27/58)，明显高于对照组的
20.69%，差异均有统计学意义(P<0.05)；观察组患者 3年总生存率为 87.93% (51/58)，明显高于对照组的 70.69%
(41/58)，且观察组 3年无转移生存率以及 3年无复发生存率均明显高于对照组，差异均有统计学意义(P<0.05)。
结论 希罗达联合同步放化疗对晚期直肠癌患者具有很好的治疗效果，其不仅减少了治疗后血液学相关水平的波
动频率，而且有效增加了治疗后生存率，在临床上具有较高的推广应用价值。

      【关键词】 晚期直肠癌；希罗达；放化疗；生存率

      【中图分类号】 R735.3+7 【文献标识码】 A 【文章编号】 1003—6350（2016）12—1951—03


Clinical effect of xeloda combined with concurrent chemoradiotherapy in the treatment of advanced colorectal
cancer.
WU Xin 1, DU Min 1, JIANG Yu-ting 1, HU Xiao-li 1, CAI Dong-yan 2. Department of pharmacy 1, Department of
Oncology 2, the Fourth People's Hospital of Wuxi City, Wuxi 214062, Jiangsu, CHINA

【Abstract】 Objective To observe the clinical effect of xeloda combined with radiotherapy and chemotherapy
in the treatment of patients with advanced rectal cancer. Methods A total of 116 patients with advanced rectal cancer,
who admitted to the Department of Oncology of our hospital from April 2010 to December 2012, were randomly divided
into observation group and control group by digital method, with 58 cases in each group. The control group was given
chemotherapy with Xeloda alone, and the observation group received xeloda combined with radiotherapy treatment. The
treatment effect, adverse reactions after treatment, complications, and survival record during 3-year follow-up of the two
groups were compared. Results The complete responses (CR) and efficacy of the observation group [45.55% (27/
58), 81.03% (47/58), respectively] were significantly higher than those of the control group [27.59% (16/58), 56.09%
(33/58), respectively], P<0.05. The reduced proportion rate of platelet, hemoglobin and lymphocytes in the observation
group 34.48% (20/58), 20.69% (21/58), 15.52% (9/58), respectively were significantly lower than those of the control
group 53.45% (31/58), 39.66% (23/58), 31.03% (18/58) respectively, P<0.05. Appear radiation proctitis proportion rate
of observation group 46.55% (27/58) was significantly higher than that of the control group 20.69% (12/58), P<0.05.
The 3 years overall survival rate of observation group [87.93% (51/58)] was significantly higher than that of the control
group [70.69% (41/58)], and the 3 years without metastasis survival rate and 3 years recurrence-free survival rate in the
observation group were significantly higher than those in the control group (P<0.05). Conclusion Xeloda combined with
synchronous radiotherapy and chemotherapy has a very good therapeutic effect in the treatment of advanced colorectal can-
cer, which not only reduces the fluctuation frequency of hematological correlated level after treatment, but also effectively in-
creases the survival rate for after operation. It has a high value in the clinical application and promotion.

      【Key words】 Advanced rectal cancer; Xeloda; Radiotherapy and chemotherapy; Survival rate
·论 著·
6350.2016.12.017